African American Men With Very Low-Risk Prostate Cancer Exhibit Adverse Oncologic Outcomes After Radical Prostatectomy: Should Active Surveillance Still Be an Option for Them?

All authors: Johns Hopkins University, Baltimore, MD.
Journal of Clinical Oncology (Impact Factor: 18.43). 06/2013; 31(24). DOI: 10.1200/JCO.2012.47.0302
Source: PubMed

ABSTRACT PURPOSEActive surveillance (AS) is a treatment option for men with very low-risk prostate cancer (PCa); however, favorable outcomes achieved for men in AS are based on cohorts that under-represent African American (AA) men. To explore whether race-based health disparities exist among men with very low-risk PCa, we evaluated oncologic outcomes of AA men with very low-risk PCa who were candidates for AS but elected to undergo radical prostatectomy (RP). PATIENTS AND METHODS
We studied 1,801 men (256 AA, 1,473 white men, and 72 others) who met National Comprehensive Cancer Network criteria for very low-risk PCa and underwent RP. Presenting characteristics, pathologic data, and cancer recurrence were compared among the groups. Multivariable modeling was performed to assess the association of race with upgrading and adverse pathologic features.ResultsAA men with very low-risk PCa had more adverse pathologic features at RP and poorer oncologic outcomes. AA men were more likely to experience disease upgrading at prostatectomy (27.3% v 14.4%; P < .001), positive surgical margins (9.8% v 5.9%; P = .02), and higher Cancer of the Prostate Risk Assessment Post-Surgical scoring system (CAPRA-S) scores. On multivariable analysis, AA race was an independent predictor of adverse pathologic features (odds ratio, [OR], 3.23; P = .03) and pathologic upgrading (OR, 2.26; P = .03). CONCLUSIONAA men with very low-risk PCa who meet criteria for AS but undergo immediate surgery experience significantly higher rates of upgrading and adverse pathology than do white men and men of other races. AA men with very low-risk PCa should be counseled about increased oncologic risk when deciding among their disease management options.

Download full-text


Available from: Debasish Sundi, Apr 11, 2014
1 Follower
  • Source
    • "The degree to which biologic/genetic differences, socioeconomic determinants, delayed diagnosis, access to care, and patterns of care contribute to poorer CaP outcomes for AA men is largely unknown [12]. Although efforts have been made to elucidate the effect of these factors on racial disparities in CaP outcomes [13] [14] [15] [16], there is a paucity of literature examining the relationship between insurance status and racial disparities and its association with cancer care patterns in the context of aggressive cancers. With the implementation of the Affordable Care Act (ACA) and ongoing expansion of health insurance coverage, it is critically important to understand the influence health insurance may have on racial treatment patterns in cancer care [17]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: Treating high-risk prostate cancer (CaP) with definitive therapy improves survival. We evaluated whether having health insurance reduces racial disparities in the use of definitive therapy for high-risk CaP. Materials and methods: The Surveillance, Epidemiology, and End Results Program was used to identify 70,006 men with localized high-risk CaP (prostate-specific antigen level 4 20 ng/ml or Gleason score 8–10 or stage 4 cT3a) diagnosed from 2007 to 2010. We used multivariable logistic regression to analyze the 64,277 patients with complete data to determine the factors associated with receipt of definitive therapy. Results: Compared with white men, African American (AA) men were significantly less likely to receive definitive treatment (adjusted odds ratio [AOR] ¼ 0.60; 95% CI: 0.56–0.64; P o 0.001) after adjusting for sociodemographics and known CaP prognostic factors. There was a significant interaction between race and insurance status (P interaction ¼ 0.01) such that insurance coverage was associated with a reduction in racial disparity between AA and white patients regarding receipt of definitive therapy. Specifically, the AOR for definitive treatment for AA vs. white was 0.38 (95% CI: 0.27–0.54, P o 0.001) among uninsured men, whereas the AOR was 0.62 (95% CI: 0.57–0.66, P o 0.001) among insured men. Conclusions: AA men with high-risk CaP were significantly less likely to receive potentially life-saving definitive treatment when compared with white men. Having health insurance was associated with a reduction in this racial treatment disparity, suggesting that expansion of health insurance coverage may help reduce racial disparities in the management of aggressive cancers. r
    Urologic Oncology 12/2014; 32(8):1285-1291. DOI:10.1016/j.urolonc.2014.04.014 · 3.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The implementation of prostate-specific antigen (PSA) screening has coincided with a decrease in mortality rate from prostate cancer at the cost of overtreatment. Active surveillance has thus emerged to address the concern for over-treatment in men with low-risk prostate cancer.
  • Source
    Journal of Clinical Oncology 07/2013; 31(24). DOI:10.1200/JCO.2013.50.7723 · 18.43 Impact Factor
Show more